4576 Share Price Performance
JP¥0
-117.00 (-100.00%)
Price JP¥0
Share Pricen/a
D. Western Therapeutics Institute, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
4576 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
D. Western Therapeutics Institute, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -11.65
- 89.97%
- -163.07%
- 42.2%
About 4576
- Founded
- 1999
- Employees
- 21
- CEO
- WebsiteView website
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
